Pimecrolimus Cream for Oral Lichen Planus

Overview

Study investigating the use of pimecrolimus 1% cream for oral lichen planus

Full Title of Study: “A 6-week Randomized, Double-blind, Vehicle-controlled Pilot Study With a 6-week Open Label Extension to Assess the Efficacy and Safety of Pimecrolimus 1% Cream in the Treatment of Oral Lichen Planus”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: February 2009

Detailed Description

Lichen planus (LP) is an idiopathic inflammatory dermatosis of the skin and mucous membranes. Cutaneous lesions present as pink polygonal papules on the flexor wrists, trunk, thighs, shin and the dorsal hands. Oral lichen planus (OLP) represents a unique subset of LP and is often the sole manifestation of this disease. Clinically, the lesions can be reticulate, erythematous, atrophic or erosive, with the erosive form being the most common. Lesions can be found anywhere in the oral mucosa and are associated with burning pain which is worsened while eating. The risk of development of squamous cell carcinoma has been estimated to be as high as 5%. Treatments for oral lichen planus involve high potency topical steroid, systemic steroids, oral/topical retinoids and immunosuppressants. However, the long term side effects of steroids (e.g. striae, skin atrophy, telangiectasias, tachyphylaxis, secondary candidiasis and perioral dermatitis) prevent more extensive utilization except in the most severe cases. Given the debilitating nature of OLP, risk of malignant transformation, and long term side effects associated with current therapies, a safe intervention is needed for this disorder. Tacrolimus and pimecrolimus may have fewer side affects than topical steroids. Recently, in an open label trial of 19 patients with recalcitrant erosive lichen planus, tacrolimus decreased the area of ulceration by 73% after an eight week course. Local irritation was the most common side effect. However, tacrolimus comes in an ointment base, a poorly tolerated vehicle for oral lesions. Topical treatment of oral lesions has also been compromised by problems with maintaining sufficient contact time between poorly adherent cream and ointment preparations and moist mucous membrane surfaces. This study is designed to evaluate the topical application of pimecrolimus 1% cream when applied twice daily with occlusion in the treatment of oral lichen planus.

Interventions

  • Drug: Pimecrolimus 1% cream
    • pimecrolimus cream or matching placebo BID for 6 weeks

Arms, Groups and Cohorts

  • Active Comparator: 1
    • “During the 6-week double-blind phase, all patients will be randomly assigned to receive either pimecrolimus 1% cream or its vehicle twice daily with occlusion on the affected areas. Topical application of pimecrolimus1% cream for oral erosive lichen planus for a duration of 6 weeks; ¼ gram of cream will be applied to each of the 2 sides of the mouth BID with a 2×2 gauze.”
  • Placebo Comparator: 2
    • “During the 6-week double-blind phase, all patients will be randomly assigned to receive either pimecrolimus 1% cream or its vehicle twice daily with occlusion on the affected areas. Topical application of pimecrolimus1% cream for oral erosive lichen planus for a duration of 6 weeks; ¼ gram of cream will be applied to each of the 2 sides of the mouth BID with a 2×2 gauze.”

Clinical Trial Outcome Measures

Primary Measures

  • The Primary Efficacy Variable Was the Change in the Investigator’s Global Assessment of the Overall Severity of Disease From Baseline to Week 6.
    • Time Frame: 0, 1, 2, 4, 6 weeks
    • The primary efficacy variable was the change in the Investigator’s Global Assessment of the overall severity of disease from baseline to week 6. Scale is 0-4. 0 is no disease. 4 is worst disease. Minimum score is 0. Maximum score is 4. Measurments were completed day 0, week 1, week 2, week 4, and week 6. Scores are listed at baseline (day 0) and end of study (week 6).

Secondary Measures

  • The Secondary Efficacy Variables Was Changes Erythema and Assessment of Spontaneous Pain on a Visual Analog Scale (0-10).
    • Time Frame: 0, 1, 2, 4, 6 weeks
    • The secondary efficacy variables were change in the size of the target erosion, erythema and assessment of spontaneous pain on a visual analog scale (0-10). The scale used to measure erythema is 0-3. 0 is no erythema, 1 is mild erythema, 2 is moderate erythema, and 3 is severe erythema. Minimum score is 0. Maximum score is 3. Spontaneous pain was scored on a scale of 0-10 (0 no pain, 10 severe pain). Measurments were completed day 0, week 1, week 2, week 4, and week 6. Scores are listed at baseline (day 0) and end of study (week 6).
  • The Secondary Efficacy Variable Was Change in the Size of a Target Erosion in Millimeters.
    • Time Frame: 0, 1, 2, 4, 6 weeks
    • Secondary outcome variable was change in size of the target erosion in millimeters from baseline compared to week 6.

Participating in This Clinical Trial

Inclusion Criteria

  • Of any gender, 18 years or older. – With a diagnosis of oral lichen planus previously proven on biopsy. – With at least one erosion at baseline (baseline IGA of 2 or greater). – Signed written informed consent. – Willingness and ability to comply with the study requirements. – Negative blood pregnancy tests must be documented for all females of childbearing potential prior to enrollment. Exclusion Criteria:

  • Who have received systemic immunosuppressants (e.g. corticosteroids), or oral retinoids, or any other systemic therapies known or suspected to have an effect on oral lichen planus within 4 weeks prior to participation in the study. – Who have been treated with topical therapy (e.g., topical corticosteroids, pimecrolimus, tacrolimus, or topical retinoids, etc) or any other topical therapies known or suspected to have an effect on oral lichen planus within two weeks prior to participation in the study. – Who are immunocompromised (e.g., lymphoma, AIDS, Wiskott-Aldrich Syndrome) or have an evidence of malignant disease. – Who have systemic or generalized infections (bacterial, viral or fungal). – Who have a clinically relevant liver disorder (transaminase enzymes >3 x ULN) or renal disorder (serum creatinine > 10% above upper normal limit). – Who have unstable or uncontrolled diabetes or hypertension. – Who are currently receiving or are intended to be treated with any potent inhibitor of the enzyme CYP450 3A4. Treatment with substrates or moderately potent inhibitors of CYP450 3A4 is permitted during the study, under close monitoring for adverse events during that period. – Menstruating females of childbearing potential who are not using a medically accepted method of contraception during the study. Medically approved contraception may, at the discretion of the investigator, include abstinence. – Women who are breastfeeding. – Who had received an investigational drug within four weeks prior to the study or who intended to use other investigational drugs during the course of this study. – Who are hypersensitive to pimecrolimus or any of the components of the cream. – Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study. – Who have a history of substance abuse or any factor, which limits the subject's ability to cooperate with the study procedures. – Who are uncooperative, known to miss appointments (according to subjects' records) and are unlikely to follow medical instructions or are not willing to attend regular visits. – History of Netherton's syndrome – Patients with lymphadenopathy

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Utah
  • Collaborator
    • Novartis
  • Provider of Information About this Clinical Study
    • Principal Investigator: Christopher Hull, Associate Professor, Dermatology – University of Utah
  • Overall Official(s)
    • Christopher Hull, MD, Principal Investigator, University of Utah

Citations Reporting on Results

McCaughey C, Machan M, Bennett R, Zone JJ, Hull CM. Pimecrolimus 1% cream for oral erosive lichen planus: a 6-week randomized, double-blind, vehicle-controlled study with a 6-week open-label extension to assess efficacy and safety. J Eur Acad Dermatol Venereol. 2011 Sep;25(9):1061-7. doi: 10.1111/j.1468-3083.2010.03923.x. Epub 2010 Dec 22.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.